EyePoint (EYPT) Change in Acquisitions & Divestments (2010 - 2026)
EyePoint (EYPT) posted Change in Acquisitions & Divestments of $70.0 million for Q1 2026, down 6.67% sequentially from $75.0 million in Q4 2025, and down 11.64% YoY from $79.2 million in Q1 2025.
Analysis
EyePoint (EYPT) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
EyePoint has reported Change in Acquisitions & Divestments for 13 years, with the latest figure at $70.0 million in Q1 2026.
- Quarterly Change in Acquisitions & Divestments fell 11.64% year-over-year to $70.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.5 million (up 30.92% YoY) and the FY2025 annual result came in at $323.7 million, up 76.9% from the prior year.
- Change in Acquisitions & Divestments eased to $70.0 million in Q1 2026 per EYPT's latest filing, from $75.0 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $103.5 million in Q2 2025 and troughed at $3.0 million in Q4 2023.
- A 5-year average of $47.3 million and a median of $44.0 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
- The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments plunged 93.62% in 2023, then jumped 2183.33% in 2024.
- Over 5 years, Change in Acquisitions & Divestments stood at $47.0 million in 2022, then slumped by 93.62% to $3.0 million in 2023, then surged by 2183.33% to $68.5 million in 2024, then climbed by 9.49% to $75.0 million in 2025, then slipped by 6.67% to $70.0 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $70.0 million, $75.0 million, and $66.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.00 Mn |
| Mar 31, 2026 | 70.00 Mn |
| Dec 31, 2025 | 75.00 Mn |
| Sep 30, 2025 | 66.00 Mn |
| Jun 30, 2025 | 103.50 Mn |
| Mar 31, 2025 | 79.23 Mn |
| Dec 31, 2024 | 68.50 Mn |
| Sep 30, 2024 | 67.00 Mn |
| Jun 30, 2024 | 25.50 Mn |
| Mar 31, 2024 | 22.00 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Jun 30, 2023 | 16.78 Mn |
| Mar 31, 2023 | 35.50 Mn |
| Dec 31, 2022 | 47.00 Mn |
| Sep 30, 2022 | 41.00 Mn |
| Jun 30, 2022 | 30.00 Mn |
| Mar 31, 2022 | 6.00 Mn |
| Jun 30, 2017 | 2.50 Mn |
| Mar 31, 2017 | 3.35 Mn |
| Dec 31, 2016 | 5.39 Mn |